Objective:

To evaluate the efficacy and safety of EYP-1901 in patients with wet AMD and DME, specifically comparing it to standard anti-VEGF therapies such as aflibercept.

Key Findings:

• EYP-1901 demonstrated statistical noninferiority to aflibercept in best-corrected visual acuity (BCVA) change in wet AMD, indicating comparable efficacy.
• Over 85% of EYP-1901-treated patients maintained stable or improved vision at 6 months, highlighting its potential effectiveness.
• EYP-1901 controlled retinal fluid dynamics effectively, with stable central subfield thickness for 6 months, suggesting good anatomical stability.
• In DME, EYP-1901 achieved extended time-to-first supplemental injection compared to aflibercept, indicating a reduced treatment burden.

Interpretation:

EYP-1901 shows promise as a durable treatment option for wet AMD and DME, potentially improving long-term visual outcomes and significantly reducing treatment burden.

Limitations:

• The trials included a limited number of participants, which may affect the generalizability of the results.
• EYP-1901 is still investigational and not yet approved for clinical use, necessitating further validation.

Conclusion:

EYP-1901 has the potential to enhance treatment outcomes in wet AMD and DME, with ongoing phase 3 trials expected to provide further insights and validate these findings.